Based on preclinical studies indicating that metformin can sensitize lung cancer cells to tyrosine kinase inhibitors (TKIs), a combination of gefitinib, a TKI-targeting mutant epidermal growth factor receptor (EGFR), and metformin was tested in nondiabetic NSCLC patients. The gene discussed is EGFR; the disease is lung cancer.